目的 探討安替可膠囊聯(lián)合卡培他濱和奧沙利鉑治療晚期結(jié)直腸癌的臨床療效。方法 選取2014年2月—2015年10月在達(dá)州市中西醫(yī)結(jié)合醫(yī)院接受治療的晚期結(jié)直腸癌患者84例，按照治療方法的差別分成對照組（42例）和治療組（42例）。對照組口服卡培他濱片，1 g/m²，2次/d；同時靜脈滴注注射用奧沙利鉑，130 mg/m²，1次/d。治療組在對照組治療基礎(chǔ)上口服安替可膠囊，2粒/次，3次/d。兩組患者均連續(xù)治療9周。觀察兩組患者的臨床療效，同時比較治療前后兩組患者血清基質(zhì)金屬蛋白酶-2（MMP-2）和基質(zhì)金屬蛋白酶-9（MMP-9）水平，評價兩組患者生存質(zhì)量改善情況和不良反應(yīng)發(fā)生率。結(jié)果 治療后，對照組客觀緩解率（ORR）為40.48%，臨床獲益率（CBR）為71.43%；治療組ORR和CBR分別為61.90%、90.48%，兩組ORR、CBR比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對照組和治療組患者生存質(zhì)量改善率分別為80.95%和95.24%，兩組差異比較具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清MMP-2和MMP-9水平均較同組治療前明顯降低（P<0.05）；且治療組上述兩項(xiàng)指標(biāo)降低的更顯著（P<0.05）。治療過程中，治療組不良反應(yīng)發(fā)生率為28.57%，低于對照組的54.76%，兩組不良反應(yīng)發(fā)生率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 安替可膠囊聯(lián)合卡培他濱和奧沙利鉑治療晚期結(jié)直腸癌具有很好的臨床療效，可以降低腫瘤細(xì)胞浸潤和轉(zhuǎn)移能力，改善患者生活質(zhì)量，具有一定的臨床應(yīng)用推廣價值。

Objective To explore the clinical effect of Antike Capsules combined with capecitabine and oxaliplatin in treatment of advanced colorectal cancer. Methods Patients (84 cases) with advanced colorectal cancer in Dazhou Hospital of Chinese Traditional and Western Medicine from February 2014 to October 2015 were divided into control (42 cases) and treatment groups (42 cases) according to different treatment methods. The patients in the control group were po administered with Capecitabine Tablets, 1 g/m², twice daily; And they were iv administered with Oxaliplatin for injection, 130 mg/m², once daily. The patients in the treatment group were po administered with Antike Capsules on the basis of the control group, 2 grains/time, three times daily. The patients in two groups were treated for 9 weeks. After treatment, the clinical efficacies were observed, and the levels of MMP-2 and MMP-9 in two groups were compared before and after treatment, in the same time, the improvement of survival quality and incidence of adverse reactions were evaluated. Results After treatment, ORR and CBR in the control group respectively were 40.48% and 71.43%; Accordingly, they were 61.90% and 90.48% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the improvement rate of survival quality in the control and treatment groups were 80.95% and 95.24%, respectively, the difference was statistically significant in two groups (P<0.05). After treatment, the serum MMP-2 and MMP-9 levels in two groups were significantly decreased (P<0.05); The above two indexes in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). During treatment, the incidence of adverse reactions in the treatment group was 28.57%, which was lower than 54.76% in the control group, and there were differences between two groups (P<0.05). Conclusion Antike Capsules combined with capecitabine and oxaliplatin in treatment of advanced colorectal cancer have good clinical effect, can reduce the ability of tumor cell invasion and metastasis, and improve the quality of life, which has a certain clinical application value.